Listing 3 - Actual negotiations

Indication:

Treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by adjuvant IMFINZI monotherapy treatment after radical cystectomy.

Indication:

For the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).

Indication:

In combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.

Indication:

In combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.

Indication:

For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) in postmenopausal women as initial endocrine-based therapy.

Indication:

For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer as follows: - in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy. - in combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone (GnRH) agonist. - as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens. At least one chemotherapy...

Indication:

Indicated in combination with venetoclax for the treatment of patients with previously untreated CLL.

Indication:

In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated MCL who are ineligible for autologous stem cell transplant.

Indication:

Venclexta, in combination with ibrutinib, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)

Indication:

Calquence, in combination with venetoclex, for the treatment of patients with previously untreated chronic lymphocytic leukemia.